BCL2 and early-onset autosomal dominant Alzheimer disease: However, pre-treatment with both Hesperidin and DRB not only modulated Alzheimer's disease-related molecules but also decreased Bax and increased Bcl-2 protein levels, as well as reduced the apoptotic Bax/Bcl-2 ratio in the in vitro AD model, indicating a protective effect in apoptotic cell death against to Aβ1–42 toxicity.